news

News Oncolix

Oncolix, Inc. Announces Capital Raise of $4.2 Million

HOUSTON, TX, January 27, 2015 / — ONCOLIX, INC., announced today that it has completed a Series A round of financing, led by PoC Capital, LLC and Integrium Clinical Research, LLC. Also participating in the finance round was the Texas Emerging Technology Fund and certain healthcare-focused investors, representing gross proceeds to ONCOLIX of approximately $4.2 million. ONCOLIX plans to use the net proceeds from the offering to fund activities relating to its drug candidate, Prolanta™, for a Phase I dose-escalation clinical trial for the treatment of ovarian cancer.

Inner Sidebar

  • What We Do

    a

    What we do

    We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers.

  • Strategic Alliance

    2

    Strategic Alliance

    Oncolix has chosen BioVectra, Inc. to perform the manufacturing of Prolanta. BioVectra is the largest Canadian...

  • Conferences

    c

    Conferences

    oncolix welcomes intrest in developing a technical and financial partnership with both public and private entities

Style switcher RESET
Color scheme